- •November 16, 2002
- •February 14, 2003
- •February 21
- •February 28
- •March 7
- •March 10
- •March 12
- •March 14
- •March 15
- •March 17
- •March 19
- •March 21
- •March 24
- •March 26
- •March 28
- •March 30
- •March 31
- •April 2
- •April 2
- •April 8-10
- •April 12
- •April 16
- •April 20
- •April 20
- •April 23
- •April 25
- •April 27
- •April 29
- •June 6
- •June 13
- •June 17
- •June 21
- •June 23
- •June 24
- •July 2
- •July 5
- •August 14
- •September 8
- •September 24
- •References
- •Virology
- •Discovery of the SARS Virus
- •Initial Research
- •The Breakthrough
- •Coronaviridae
- •SARS Co-V
- •Genome Sequence
- •Morphology
- •Organization
- •Detection
- •Stability and Resistance
- •Natural Host
- •Antiviral Agents and Vaccines
- •Antiviral Drugs
- •Vaccines
- •Outlook
- •References
- •Routes of Transmission
- •Factors Influencing Transmission
- •Patient Factors in Transmission
- •Asymptomatic Patients
- •Symptomatic Patients
- •Superspreaders
- •The Unsuspected Patients
- •High-Risk Activities
- •Transmission during Quarantine
- •Transmission after Recovery
- •Animal Reservoirs
- •Conclusion
- •References
- •Introduction
- •Modeling the Epidemic
- •Starting Point
- •Global Spread
- •Hong Kong
- •Vietnam
- •Toronto
- •Singapore, February 2003
- •China
- •Taiwan
- •Other Countries
- •Eradication
- •Outlook
- •References
- •Introduction
- •International Coordination
- •Advice to travelers
- •Management of SARS in the post-outbreak period
- •National Measures
- •Legislation
- •Extended Case Definition
- •Quarantine
- •Reduce travel between districts
- •Quarantine after Discharge
- •Infection Control in Healthcare Settings
- •General Measures
- •Protective Measures
- •Hand washing
- •Gloves
- •Face Masks
- •Additional protection
- •Getting undressed
- •Special Settings
- •Intensive Care Units
- •Intubating a SARS Patient
- •Anesthesia
- •Triage
- •Internet Sources
- •Additional information
- •Infection Control in Households
- •Possible Transmission from Animals
- •After the Outbreak
- •Conclusion
- •References
- •Case Definition
- •WHO Case Definition
- •Suspect case
- •Probable case
- •Exclusion criteria
- •Reclassification of cases
- •CDC Case Definition
- •Diagnostic Tests
- •Introduction
- •Laboratory tests
- •Molecular tests
- •Virus isolation
- •Antibody detection
- •Interpretation
- •Limitations
- •Biosafety considerations
- •Outlook
- •Table, Figures
- •References
- •Clinical Presentation and Diagnosis
- •Clinical Presentation
- •Hematological Manifestations
- •Atypical Presentation
- •Chest Radiographic Abnormalities
- •Chest Radiographs
- •CT Scans
- •Diagnosis
- •Clinical Course
- •Viral Load and Immunopathological Damage
- •Histopathology
- •Lung Biopsy
- •Postmortem Findings
- •Discharge and Follow-up
- •Psychosocial Issues
- •References
- •Appendix: Guidelines
- •WHO: Management of Severe Acute Respiratory Syndrome (SARS)
- •Management of Suspect and Probable SARS Cases
- •Definition of a SARS Contact
- •Management of Contacts of Probable SARS Cases
- •Management of Contacts of Suspect SARS Cases
- •SARS Treatment
- •Antibiotic therapy
- •Antiviral therapy
- •Ribavirin
- •Neuraminidase inhibitor
- •Protease inhibitor
- •Human interferons
- •Human immunoglobulins
- •Alternative medicine
- •Immunomodulatory therapy
- •Corticosteroids
- •Other immunomodulators
- •Assisted ventilation
- •Non-invasive ventilation
- •Invasive mechanical ventilation
- •Clinical outcomes
- •Outlook
- •Appendix 1
- •A standardized treatment protocol for adult SARS in Hong Kong
- •Appendix 2
- •A treatment regimen for SARS in Guangzhou, China
- •References
- •Pediatric SARS
- •Clinical Manifestation
- •Radiologic Features
- •Treatment
- •Clinical Course
- •References
156 SARS Treatment
tory therapy may be decreased. Well-conducted randomized controlled trials on a sufficient number of cases are necessary to clarify the effectiveness of and controversies surrounding existing treatment regimens; however, these may not be feasible since large-scale outbreak will hopefully never be seen again with our heightened preparedness.
Appendix 1
A standardized treatment protocol for adult SARS in Hong Kong
From: So, et al. Lancet 2003;361:1615-6
(1)Antibacterial treatment
Start levofloxacin 500 mg once daily intravenously or orally
Or clarithromycin 500 mg twice daily orally plus amoxicillin and clavulanic acid 375 mg three times daily orally if patient <18 years, pregnant, or suspected to have tuberculosis
(2)Ribavirin and methylprednisolone
Add combination treatment with ribavirin and methylprednisolone when:
Extensive or bilateral chest radiographic involvement
Or persistent chest radiographic involvement and persistent high fever for 2 days
Or clinical, chest radiographic, or laboratory findings suggestive of worsening
Or oxygen saturation <95% in room air
www.SARSreference.com
Appendix 1 157
Standard corticosteroid regimen for 21 days
Methylprednisolone 1 mg/kg every 8 h (3 mg/kg daily) intravenously for 5 days
Then methylprednisolone 1 mg/kg every 12 h (2 mg/kg daily) intravenously for 5 days
Then prednisolone 0.5 mg/kg twice daily (1 mg/kg daily) orally for 5 days
Then prednisolone 0.5 mg/kg daily orally for 3 days
Then prednisolone 0.25 mg/kg daily orally for 3 days
Then off
Ribavirin regimen for 10–14 days
Ribavirin 400 mg every 8 h (1200 mg daily) intravenously for at least 3 days (or until condition becomes stable)
Then ribavirin 1200 mg twice daily (2400 mg daily) orally
(3)Pulsed methylprednisolone
Give pulsed methylprednisolone if clinical condition, chest radiograph, or oxygen saturation worsens (at least two of these), and lymphopenia persists
Give as methylprednisolone 500 mg twice daily intravenously for 2 days, then back to standard corticosteroid regimen
(4)Ventilation
Consider non-invasive ventilation or mechanical ventilation if oxygen saturation <96% while on >6 L per min oxygen or if patient complains of increasing shortness of breath
Kamps and Hoffmann (eds.)